[HTML][HTML] Priorities for cancer research in low-and middle-income countries: a global perspective
Cancer research currently is heavily skewed toward high-income countries (HICs), with little
research conducted in, and relevant to, the problems of low-and middle-income countries …
research conducted in, and relevant to, the problems of low-and middle-income countries …
Advances in antibody-based therapy in oncology
S Zinn, R Vazquez-Lombardi, C Zimmermann, P Sapra… - Nature cancer, 2023 - nature.com
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …
Recent advances in the management of metastatic prostate cancer
Management of metastatic prostate cancer has undergone a revolution over the past decade
with the introduction of several novel agents and repurposing of others. Several clinical trials …
with the introduction of several novel agents and repurposing of others. Several clinical trials …
[HTML][HTML] Progress and future directions with peptide-drug conjugates for targeted cancer therapy
J Lindberg, J Nilvebrant, PÅ Nygren, F Lehmann - Molecules, 2021 - mdpi.com
We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as
cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug …
cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug …
[HTML][HTML] Radiotheranostics-precision medicine in nuclear medicine and molecular imaging
Abstract'See what you treat and treat what you see, at a molecular level', could be the motto
of theranostics. The concept implies diagnosis (imaging) and treatment of cells (usually …
of theranostics. The concept implies diagnosis (imaging) and treatment of cells (usually …
[HTML][HTML] Radiolabeled PSMA inhibitors
Simple Summary Prostate cancer remains one of the leading causes of cancer death in men
worldwide. Despite the recent success in the development and clinical application of …
worldwide. Despite the recent success in the development and clinical application of …
Peptide receptor radionuclide therapy
J Hofland, T Brabander, FA Verburg… - The Journal of …, 2022 - academic.oup.com
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …
positron emission tomography or single photon emission computed tomography imaging …
[HTML][HTML] Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications
B Sheehan, C Guo, A Neeb, A Paschalis… - European urology …, 2022 - Elsevier
Context Prostate-specific membrane antigen (PSMA) is a promising, novel theranostic target
in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in …
in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in …
Radiation dosimetry in 177Lu-PSMA-617 therapy
Radionuclide therapy using the small molecule PSMA bound to the beta-emitting
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …
Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis
The aim of the study was to assess the outcome of patients with metastatic castration-
resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) …
resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) …